Skip to main content
. Author manuscript; available in PMC: 2024 Jul 15.
Published in final edited form as: J Am Chem Soc. 2023 Jun 16;145(25):14155–14163. doi: 10.1021/jacs.3c05159

Figure 6: The proteomic analysis of TCO-ARV-771 and crPROTAC.

Figure 6:

HeLa cells were treated with either compound 0.4 μM TCO-ARV-771, or 1 μM c(RGDyK)-Tz (3 h, pretreatment) + 0.4 μM TCO-ARV-771 for 16 h. Lysates were subjected to mass spec-based proteomics analysis. A) Volcano plot shows protein abundance (log2) as a function of significance level (-log10). B) Heat map analysis to screen between TCO-ARV-771 and crPROTAC groups (TCO-ARV-771 + c(RGDyK)-Tz, 3 h).